Britannia Pharmaceuticals Limited
41-51 Brighton Road
Redhill
Surrey
RH1 6YS
Tel: 44-0-1737-773741
Fax: 44-0-1737-762672
Website: http://www.britannia-pharm.co.uk/
5 articles about Britannia Pharmaceuticals Limited
-
Britannia Pharmaceuticals Ltd: Phase 3 TOLEDO Study Shows Apomorphine Infusion Provides Effective Relief of Persistent Motor Fluctuations in Parkinson's Disease (PD) Patients Whose Symptoms are Uncontrolled With Oral Medication
8/3/2018
Britannia Pharmaceuticals Ltd has announced publication of the results of the double-blind phase of the TOLEDO study in Lancet Neurology[1].
-
Britannia Pharmaceuticals Limited: Landmark Apomorphine Study Confirms Its Established Role As A Highly Effective Treatment For Parkinson's Disease Patients Whose Symptoms Cannot Be Controlled On Standard Therapies
4/26/2017
-
Ipsen Sells the North American1 Development and Marketing Rights for Apokyn® to Britannia Pharmaceuticals Limited, Achieving a Key Milestone in the Execution of its New North American Strategy
11/3/2011
-
Ipsen Sells the North American1 Development and Marketing Rights for Apokyn® to Britannia Pharmaceuticals Limited, Achieving a Key Milestone in the Execution of its New North American strategy
11/2/2011
-
Kyowa Hakko Kogyo Co., Ltd. To Introduce Self-Injectable Drug For Treating Parkinson's Disease From Britannia Pharmaceuticals Limited
2/23/2006